Találati lista | Tudóstér

001-es BibID:	BIBFORM013825
Első szerző:	Decousus, Hervé
Cím:	Fondaparinux for the Treatment of Superficial-Vein Thrombosis in the Legs / Hervé Decousus, Paolo Prandoni, Patrick Mismetti, Rupert M. Bauersachs, Zoltán Boda, Benjamin Brenner, Silvy Laporte, Lajos Matyas, Saskia Middeldorp, German Sokurenko, Alain Leizorovicz, The CALISTO Study Group
Dátum:	2010
Megjegyzések:	The efficacy and safety of anticoagulant treatment for patients with acute, symptomaticsuperficial-vein thrombosis in the legs, but without concomitant deep-veinthrombosis or symptomatic pulmonary embolism at presentation, have not been established.MethodsIn a randomized, double-blind trial, we assigned 3002 patients to receive either fondaparinux,administered subcutaneously at a dose of 2.5 mg once daily, or placebo for45 days. The primary efficacy outcome was a composite of death from any cause orsymptomatic pulmonary embolism, symptomatic deep-vein thrombosis, or symptomaticextension to the saphenofemoral junction or symptomatic recurrence ofsuperficial-vein thrombosis at day 47. The main safety outcome was major bleeding.The patients were followed until day 77.ResultsThe primary efficacy outcome occurred in 13 of 1502 patients (0.9%) in the fondaparinuxgroup and 88 of 1500 patients (5.9%) in the placebo group (relative riskreduction with fondaparinux, 85%; 95% confidence interval [CI], 74 to 92; P<0.001).The incidence of each component of the primary efficacy outcome was significantlyreduced in the fondaparinux group as compared with the placebo group, except forthe outcome of death (0.1% in both groups). The rate of pulmonary embolism ordeep-vein thrombosis was 85% lower in the fondaparinux group than in the placebogroup (0.2% vs. 1.3%; 95% CI, 50 to 95; P<0.001). Similar risk reductions wereobserved at day 77. A total of 88 patients would need to be treated to prevent oneinstance of pulmonary embolism or deep-vein thrombosis. Major bleeding occurredin one patient in each group. The incidence of serious adverse events was 0.7% withfondaparinux and 1.1% with placebo.ConclusionsFondaparinux at a dose of 2.5 mg once a day for 45 days was effective in the treatmentof patients with acute, symptomatic superficial-vein thrombosis of the legsand did not have serious side effects.
Tárgyszavak:	Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
Megjelenés:	The New England Journal of Medicine. - 363 : 13 (2010), p. 1222-1232. -
További szerzők:	Prandoni, Paolo Mismetti, Patrick Bauersachs, Rupert M. Boda Zoltán (1947-) (belgyógyász, haematologus, klinikai onkológus) Brenner, Benjamin Laporte, Silvy Mátyás Lajos Middeldorp, Saskia Sokurenko, German Leizorovicz, Alain The CALISTO Study Group
Internet cím:	Intézményi repozitóriumban (DEA) tárolt változat DOI elektronikus változat
Borító:
Saját polcon:

001-es BibID:	BIBFORM034361
Első szerző:	Sanson, Bernd-Jan
Cím:	Safety of Low-Molecular-Weight Heparinin pregnancy : a systematic review / Bernd-Jan Sanson, Anthonie W. A. Lensing, Martin H. Prins, Jeffrey S. Ginsberg, Zinovly S. Barkagan, Edith Lavenne-Pardonge, Benjamin Brenner, Mordechay Dulitzky, Jorn D. Nielsen,Zoltan Boda, Susanna Turi, Melvin R. Mac Gillavry, Karly Hamulyák, Ingrid M. Theunissen, Beverley J. Hunt, Harry R. Büller
Dátum:	1999
Megjegyzések:	Unfractionated heparin (UFH) remains the anticoagulant of choice during pregnancy. Low-molecular-weight heparins (LMWH) are an attractive alternative to UFH due to their logistic advantages and their association with a lower incidence of osteoporosis and HIT. We reviewed all published clinical reports concerning the use of LMWH during pregnancy. In addition, participants of an international interest group contributed a cohort of pregnant women treated with LMWH. Pregnancies were divided into two groups; those with and those without maternal comorbid conditions. The number of adverse fetal outcomes and the occurrence of maternal complications were evaluated in the two groups. In the group of women with comorbid conditions (n = 290), 13.4% of the pregnancies were associated with an adverse fetal outcome. In contrast, in the group of women without comorbid conditions (n = 196), 3.1% were associated with an adverse outcome, which is comparable to that seen in the normal population. We conclude that LMWH appear to be a safe alternative to unfractionated heparin as an anticoagulant during pregnancy.
Tárgyszavak:	Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
Megjelenés:	Thrombosis and Haemostasis. - 81 : 5 (1999), p. 668-672. -
További szerzők:	Lensing, Anthonie W. A. Prins, Martin H. Ginsberg, Jeffrey S. Barkagan, Zinovly S. Lavenne-Pardonge, Edith Brenner, Benjamin Dulitzky, Mordechay Nielsen, Jorn D. Boda Zoltán (1947-) (belgyógyász, haematologus, klinikai onkológus) Turi, Susanna Mac Gillavry, Melvin R. Hamulyák, Karly Theunissen, Ingrid M. Hunt, Beverley J. Büller, Harry R.
Internet cím:	Intézményi repozitóriumban (DEA) tárolt változat
Borító:
Saját polcon: